Outcomes of people living with acute lymphoblastic leukemia who received inotuzumab ozogamicin before a stem cell transplant: a plain language summary
Bibliographic record
Abstract
Plain Language SummaryWhat is this summary about?This summary describes results from a real-world study that looked at people with a type of blood cancer called acute lymphoblastic leukemia (also known as ALL). People in the study received a medicine called inotuzumab ozogamicin (also known as inotuzumab) and then received a stem cell transplant for their ALL. Researchers looked at how long people in the study lived after their transplant and how many people died for reasons related and unrelated to relapse. They also looked at how many people developed side effects, including a potentially life-threatening condition called veno-occlusive disease or sinusoidal obstruction syndrome (also known as VOD/SOS).What were the results?Over half the people (54%) in this study were alive 18 months after their transplant. Around 2 in 10 (22%) people died within 18 months of their transplant from reasons unrelated to relapse, and around 2 in 10 (24%) people died from reasons related to relapse.Around 1 in 10 (14%) people in this study developed VOD/SOS within 100 days of their transplant. People who received two medicines called alkylators to prepare them for their transplant were more likely to develop VOD/SOS than those who did not.What do the results mean?In this real-world study, the proportion of people with ALL who developed VOD/SOS after taking inotuzumab and receiving a stem cell transplant was similar to what has been observed in clinical trials. However, fewer people in this real-world study died from reasons unrelated to relapse than in clinical trials. People who received two medicines called alkylators to prepare them for their stem cell transplant were more likely to develop VOD/SOS.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.002 | 0.013 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.002 |
| Bibliometrics | 0.002 | 0.003 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.002 |
| Open science | 0.000 | 0.001 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.006 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".